Bayer has received approval for a supplemental Biologics License Application (sBLA) from the U.S. Food and Drug Administration (FDA) in regards to their myBETAapp™ and the BETACONNECT Navigator™. These platforms utilize software to allow patients with multiple sclerosis to auto-administer BETASERON.

The 320,000 patients diagnosed with relapsing-remitting form of multiple sclerosis (RRMS) are prescribed injectable beta-interferons. With the myBETAapp and the BETACONNECT Navigator, patients are able to use Bluetooth technology to connect their autoinjector with the app to share injection data with healthcare providers. The BETACONNECT Navigator allows for the viewing of data by the patient’s healthcare team in order to become more informed on a patient particular care by viewing history and providing support.

"Since introducing the first FDA approved treatment option for relapsing remitting multiple sclerosis patients more than two decades ago, we've listened closely to the community to understand their needs and how we can support them," said Mark Rametta, D.O., FACOI, FACP, Bayer's medical director for Neurology. "The myBETAapp and BETACONNECT Navigator add to the services that we've developed based on patient feedback, including 24/7 access to nurse support and the first and only electronic autoinjector for patients taking BETASERON."

Patients manually injecting medication can also use the my BETAapp to record information and share data with their providers. The app will be available in mid-July on the Apple app story and Google Play.

"The myBETAapp and BETACONNECT Navigator work cohesively together to support communication and connection between people living with relapsing remitting multiple sclerosis and their BETA Nurse and health care team," said Daniel Kantor, M.D., FAAN and President Emeritus, Florida Society of Neurology.